These results somewhat confirmed that only a few cases of BE–EAC oncogenic development are actually based on the usual oncologic suppressor genes (TP53, SMAD4, or CDKN2A) followed by oncogene amplification, while it seems more likely that genetic diversity is maintained throughout the process (46). The gene discussed is CDKN2A; the disease is Barrett esophagus.